Melanoma immunotherapy has a critical limitation: 40 to 60% of patients don’t respond. Arielle Elkrief, MD, discusses an innovative approach targeting the gut microbiome. By using fecal microbiota…
Muneeb Shah MD, and Luke Maxfield, MD, break down the essentials of skin cancer, explaining the causes, symptoms, and treatments of basal cell carcinoma, squamous cell carcinoma, and…
Rahul Seth, DO, assistant professor of medicine at Upstate University Hospital, provides recommendations for the treatment of melanoma. For patients with unresectable melanoma, Dr. Seth recommends a combination…
Isabella C. Glitza Oliva, MD, PhD, MS, assistant professor in the Department of Melanoma Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer…
Gal Markel, MD, PhD, chief scientist and senior oncologist at Sheba Medical Center, discusses the use of fecal microbiota transplant (FMT) for melanoma patients nonresponsive to PD-1 inhibition.…
Christian U. Blank, MD, PhD, medical oncologist in the Division of Immunology at the Netherlands Cancer Institute, provides a three year update for the first clinical trial for the…
Georgina V. Long, BSc, PhD, MBBS, co-medical director of Melanoma Institute Australia (MIA), chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital…
Ragini R. Kudchadkar, MD, associate professor Department of Hematology and Medical Oncology, associate director of Hematology and Medical Oncology Fellowship Program – Clinical/Service at Emory University School of…
Craig L. Slingluff Jr, MD, director of surgical oncology at the Emily Couric Clinical Cancer Center at the University of Virginia, discusses the use of seviprotimut-L vaccine against…
In an interview during the 2020 OncLive® State of the Science Summit™ on Advanced Melanoma, Tracey Liebman, MD, assistant professor in the Ronald O. Perelman Department of Dermatology at the NYU…
In a study of patients with advanced melanoma treated with single-agent nivolumab or pembrolizumab, 25.8% achieved a complete response (CR). Approximately four out of five patients with advanced…
A new multicenter study hopes to ascertain whether the adjuvant implementation of personalized cancer vaccine mRNA-4157, in combination with pembrolizumab, improves recurrence-free survival (RFS) when compared with pembrolizumab…
